User Guide
Why can I only view 3 results?
You can also view all results when you are connected from the network of member institutions only. For non-member institutions, we are opening a 1-month free trial version if institution officials apply.
So many results that aren't mine?
References in many bibliographies are sometimes referred to as "Surname, I", so the citations of academics whose Surname and initials are the same may occasionally interfere. This problem is often the case with citation indexes all over the world.
How can I see only citations to my article?
After searching the name of your article, you can see the references to the article you selected as soon as you click on the details section.
 Views 19
 Downloands 2
Antrasiklin ve taksan rezistant metastatik meme kanseri tedavisinde eribulin mesilat etkinlik ve tolerabilitesi. Tek merkez deneyimi.
2019
Journal:  
Ortadoğu Tıp Dergisi
Author:  
Abstract:

Amaç: Mikrotübül inhibitörü olan eribulin mesilat antrasiklin ve taksana rezistant metastatik meme kanserli hastalarda kullanımı kabul edilmiştir. Amaç eribulin mesilatın etkinliğini araştırmak. Gereç ve Yöntemler: Retrospektif çalışmada İstanbul Okmeydanı eğitim ve araştırma hastanesi tıbbi onkoloji kliniğinde metastatik meme kanseri nedeniyle tedavi görmekte olan ve öncesinde antrasiklin ve taksan dahil olmak üzere en az 2 seri kemoterapi almış olan hastalar alındı. Bulgular: Çalışmaya toplam 25 hasta alındı. Median yaş 54,9 (range 36-73) idi. median takip süresi 11.6 aydı. Hastaların %68 ER pozitif, %68 Pr pozitif, %8,3 HER2 pozitif ve %6,2 triple negatifti. Hastalardan %78 inde karaciğer, %64 ünde kemik,%36sında akciğer metastazı mevcuttu. Eribuli seri sayısı 4,4 (min3-max6) idi. Eribulin kür sayısı 6,6 (min 1-max 33) idi. Median PFS 6,6 (0-26) ay olup median OS 17 (0-30) aydı. %8 inde tam yanıt (2 hasta), %12 (3hasta) sinde parsiyel yanıt,%52 (13 hasta) stabil yanıt ve %28 (7 hasta ) progresif hastalık mevcuttu. Hastaların hormon reseptör durumu ve HER2 durumuna göre sağ kalımda farklılık yoktu(P=0,187). Hastalardaki metastaz bölgelerine göre de sağ kalım da farklılık tespit edilmedi(P=0,875). %12 (3 hasta ) hastada grade 3-4 hematolojik toksisite ve %4( 1 hasta )hastada grade 3-4 nöropati görülmüşken %40 (10 hasta ) hastada grade 1-2 hematolojik toksisite, %24 (6hasta ) hastada grade 1-2 nöropati görülmüştür. Sonuç: Eribulin mesilat antrasiklin ve taksan rezistans önceden çoklu seri kemoterapi almış metastatik meme kanserli hastaların tedavisinde 3. Seri ve daha sonraki serilerde etkin ve tolerabl bulunmuştur.

Keywords:

Antrasyclin and taxan resistant metastatic breast cancer in the treatment of eribulin mesilate effectiveness and tolerability. The only center experience.
2019
Author:  
Abstract:

Aim: The microtubule inhibitor eribulin mesylate anthracycline and taxane resistance have been accepted for use in patients with metastatic breast cancer. The goal is to investigate the effectiveness of eribulin mesylate. Material and Methods: Retrospective study was carried out in New York City Medical Oncology clinic patients who were treated for metastatic breast cancer and who had received at least 2 serial chemotherapy including anthracycline and taxan. Results: A total of 25 patients were included in the study. Median age was 54.9 (range 36-73). Median follow-up time is 11.6 months. 68% of the patients were ER positive, 68% were Pr positive, 8.3% were HER2 positive and 6.2% were triple negative. 78% of the patients had liver, 64% had bone, and 36% had lung metastases. The treatment line number was 4.4 (min3-max6). The number of cycles of Eribulin was 6.6 (min 1-max 33). Median PFS is 6.6 (0-26) months and median OS is 17 (0-30). There were 8% complete response (2 patients), 12% (3 patients) partial response, 52% (13 patients) stable response and 28% (7 patients) progressive disease. There was no difference in survival according to patients' hormone receptor status and HER2 status (P = 0.187). There was no difference in survival according to the metastatic sites in the patients (P = 0.875). Grade 3 to 4 hematologic toxicity in 12% (3 patients) and grade 3-4 neuropathy in 4% (1 patient) in the patient,40% (10 patients) grade 1-2 hematologic toxicity in the patient, grade 1-2 neuropathy were seen Conclusion: Eribulin mesylate have been found to be effective and tolerable in line 3 and more than subsequent line in the treatment of patients with metastatic breast cancer who anthracycline and taxan resistance and previously received multiple line chemotherapy.

Keywords:

Efficacy and Tolerability Of Eribulin Mesylate In The Treatment Of Anthracycline and Taksan Resistance To Metastatic Breast Cancer. Single Central Experience
2019
Author:  
Abstract:

Aim: The microtubule inhibitor eribulin mesylate anthracycline and taxane resistance have been accepted for use in patients with metastatic breast cancer. The goal is to investigate the efficacy of eribulin mesylate. Material and Methods: Retrospective study was carried out in Istanbul Okmeydanı educational and research hospital medical oncology clinic patients who were treated for metastatic breast cancer and who had received at least 2 serial chemotherapy including anthracycline and taksan. Results: A total of 25 patients were included in the study. Median age was 54.9 (range 36-73). Median follow-up time is 11.6 months. 68% of the patients were ER positive, 68% were Pr positive, 8.3% were HER2 positive and 6.2% were triple negative. 78% of the patients had liver, 64% had bone, and 36% had lung metastases. The treatement line number was 4.4 (min3-max6). The number of cycles of Eribulin was 6.6 (min 1-max 33). Median PFS is 6.6 (0-26) months and median OS is 17 (0-30). There were 8% complete response (2 patients), 12% (3 patients) partial response, 52% (13 patients) stable response and 28% (7 patients) progressive disease. there was no difference in survival according to patients' hormone receptor status and HER2 status (P = 0.187). There was no difference in survival according to the metastatic sites in the patients (P = 0.875). Grade 3 to 4 hematologic toxicity in 12% (3 patients) and grade 3-4 neuropathy in 4% (1 patient) in the patient,40% (10 patients) grade 1-2 hematologic toxicity in the patient, grade 1-2 neuropathies were seen  Conclusion: Eribulin mesylate have been found to be effective and tolerable in line 3 and more than subsequent line in the treatment of patients with metastatic breast cancer who anthracycline and taksan resistance and previously received multiple line chemotherapy.

Keywords:

Citation Owners
Information: There is no ciation to this publication.
Similar Articles












Ortadoğu Tıp Dergisi

Field :   Sağlık Bilimleri

Journal Type :   Ulusal

Metrics
Article : 312
Cite : 165
Ortadoğu Tıp Dergisi